Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression

Jurij Hanžel; Rocio Sedano; Jenny Jeyarajah; Guangyong Zou; Stefanie C McFarlane; Christopher Ma; Vipul Jairath

doi:10.1093/ibd/izac018

Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression

Inflamm Bowel Dis. 2022 Sep 1;28(9):1462-1464. doi: 10.1093/ibd/izac018.

Authors

Jurij Hanžel^{1

2

3}, Rocio Sedano^{2

4}, Jenny Jeyarajah², Guangyong Zou^{2

5

6}, Stefanie C McFarlane², Christopher Ma^{2

7}, Vipul Jairath^{2

4

5}

Affiliations

¹ Department of Gastroenterology, University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
² Alimentiv Inc, London, Ontario, Canada.
³ Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Academic Medical Centre, Amsterdam, the Netherlands.
⁴ Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
⁵ Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
⁶ Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
⁷ Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.

PMID: 35166778
DOI: 10.1093/ibd/izac018

No abstract available

Keywords: biologics; randomized controlled trials; speed of improvement.

Plain language summary

We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes.

Publication types

Systematic Review

MeSH terms

Antibodies, Monoclonal
Biological Products* / therapeutic use
Crohn Disease* / drug therapy
Humans
Remission Induction

Substances

Antibodies, Monoclonal
Biological Products